Gharaibeh Kamel A, Turner Stephen T, Hamadah Abdurrahman M, Chapman Arlene B, Cooper-Dehoff Rhonda M, Johnson Julie A, Gums John G, Bailey Kent R, Schwartz Gary L
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA;
Section of Nephrology, University of Chicago, Chicago, IL, USA;
Am J Hypertens. 2016 Oct;29(10):1186-94. doi: 10.1093/ajh/hpw067. Epub 2016 Jun 30.
Several approaches to initiation of antihypertensive therapy have been suggested. These include thiazide diuretics (TDs) as the first drug in all patients, initial drug selection based on age and race criteria, or therapy selection based on measures of plasma renin activity (PRA). It is uncertain which of these strategies achieves the highest control rate with monotherapy in Stage-I hypertension. We sought to compare control rates among these strategies.
We used data from the Pharmacogenomic Evaluation of Antihypertensive Responses study (PEAR) to estimate control rates for each strategy: (i) TD for all, (ii) age- and race-based strategy: Hydrochlorothiazide (HCTZ) for all blacks and for whites ≥50 years and a renin-angiotensin system inhibitor (atenolol) for whites <50 years) or (iii) a PRA based strategy: HCTZ for suppressed PRA (<0.6ng/ml/h) and atenolol for non-suppressed PRA (≥0.6ng/ml/h) despite age or race. Hypertension was confirmed prior to treatment with HCTZ (148 blacks and 218 whites) or with atenolol (146 blacks and 221 whites).
In the overall sample, using clinic blood pressure (BP) response, the renin-based strategy was associated with the greatest control rate (48.9% vs. 40.8% with the age and race-based strategy (P = 0.0004) and 31.7% with the TD for all strategy (P < 0.0001)). The findings were similar using home or by 24-hour ambulatory BP responses and within each racial subgroup.
A strategy for selection of initial antihypertensive drug therapy based on PRA was associated with greater BP control rates compared to a thiazide-for-all or an age and race-based strategy.
已提出几种启动抗高血压治疗的方法。这些方法包括将噻嗪类利尿剂(TDs)作为所有患者的首选药物,根据年龄和种族标准进行初始药物选择,或根据血浆肾素活性(PRA)测量值进行治疗选择。在I期高血压的单药治疗中,不确定这些策略中的哪一种能实现最高的控制率。我们试图比较这些策略之间的控制率。
我们使用抗高血压反应的药物基因组学评估研究(PEAR)的数据来估计每种策略的控制率:(i)所有人使用TD,(ii)基于年龄和种族的策略:所有黑人以及年龄≥50岁的白人使用氢氯噻嗪(HCTZ),年龄<50岁的白人使用肾素-血管紧张素系统抑制剂(阿替洛尔),或(iii)基于PRA的策略:无论年龄或种族,PRA抑制(<0.6ng/ml/h)者使用HCTZ,PRA未抑制(≥0.6ng/ml/h)者使用阿替洛尔。在使用HCTZ(148名黑人及218名白人)或阿替洛尔(146名黑人及221名白人)治疗之前确诊为高血压。
在总体样本中,使用诊室血压(BP)反应,基于肾素的策略与最高的控制率相关(48.9%,基于年龄和种族的策略为40.8%(P = 0.0004),所有人使用TD的策略为31.7%(P < 0.0001))。使用家庭血压或24小时动态血压反应以及在每个种族亚组中,结果相似。
与所有人使用噻嗪类药物或基于年龄和种族的策略相比,基于PRA选择初始抗高血压药物治疗的策略与更高血压控制率相关。